Ecusson de la République et du canton de Genève


Changer la couleur des liensDiminuer la taille du texteAugmenter la taille du texteImprimer la page > Why Geneva

Geneva-based NovImmune enters exclusive antibody licensing agreement with Genentech


NovImmune, an antibody-focused research and development biotech company, announced that it successfully entered into an exclusive licensing agreement with Genentech Inc. a  member of the Roche Group for a proprietary anti-IL-17 fully human monoclonal antibody, and access to back-up antibodies. Recently, the IL-17 signaling pathway has received significant academic and corporate interest as its manipulation may potentially provide new treatment opportunities for major medical conditions.The anti-IL-17 antibody was generated by NovImmune’s research team and is currently in late preclinical development.For more information and full press release, please visit

This page of content is part of the files of this website. We preserve this content to provide information on historical basis. Therefore it is not updated.